Scaling Proteomics for High-Throughput CRBN Target Discovery

• Scalable proteomics platform transitioning from TMT-based discovery to DIA-enabled high-throughput profiling
• Establishment of a platform to map the CRBN target space, extending neosubstrate recognition beyond the canonical β‑hairpin G‑loop degron
• Discovery of a molecular glue degrader MRT-31619, that drives homo-dimerization of CRBN and promotes its fast, potent, and selective degradation

Speakers:

Debora Bonenfant

Vice President & Head of Proteomics

Monte Rosa Therapeutics